REPRONEX® is a purified preparation of naturally derived gonadotropins. REPRONEX® contains 75 IU follicle-stimulating hormone (FSH) and 75 IU luteinizing hormone (LH) in a 1:1 ratio. REPRONEX® stimulates eggs to mature in women whose ovaries are basically healthy but are unable to develop eggs. It is not used for women who suffer from ovarian failure.
REPRONEX® is usually used together with human chorionic gonadotropin (hCG), and is indicated for the development of multiple follicles and ovulation induction following pituitary suppression.
REPRONEX® is available by prescription in 5 mL vials containing 75 IU FSH and 75 LH activity with accompanying diluent.
REPRONEX®, in conjunction with hCG, is indicated for multiple follicular development (controlled ovarian stimulation) and ovulation induction in patients who have previously received pituitary suppression.
Important Safety Information
Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe REPRONEX®. REPRONEX®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.5%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. REPRONEX® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; the presence of any cause of infertility other than anovulation unless they are candidates for in-vitro fertilization; abnormal bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins; REPRONEX® is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.
Click here to see Full Prescribing Information for REPRONEX®.
|
